Exenatide
Byetta · Bydureon
The first GLP-1 receptor agonist brought to market, a synthetic version of exendin-4. Its short terminal half-life is why the original formulation is twice-daily, in contrast to the weekly agonists that followed.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
~2.4 h (terminal), subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied as a refrigerated prefilled pen; protect from light and do not freeze.
References
- FDA label: Byetta (NDA 021773)
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.